Context Therapeutics Inc. (CNTX) Institutional Ownership

Ownership Summary

Context Therapeutics Inc. (NASDAQ:CNTX) has 42 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 76.7% of outstanding shares in December 2025, up from 72.5% in September 2025.
• They increased total shares held in CNTX by 6.5% quarter over quarter, and investors in Context Therapeutics decreased 20.75% from a year ago.
• Of these 42 funds, 18 grew their exposure to Context Therapeutics, 9 cut back, and 15 maintained positions.
• Altogether, these fund groups held 73.0Mn shares in CNTX by December 2025, up by 4.45Mn shares quarter on quarter, and up 198.4K shares year over year.
• Blue Owl Capital Holdings LP is the top holder of Context Therapeutics as of December 31, 2025, with 14.87Mn shares representing 15.62% of outstanding stock.
• The most significant purchases of CNTX for the quarter ending December 2025 came from Blue Owl Capital Holdings LP (7.46Mn), MILLENNIUM MANAGEMENT LLC (2.6Mn), MARSHALL WACE, LLP (2.56Mn), ADAR1 Capital Management, LLC (351.09K), VANGUARD GROUP INC (290.88K).
• Leading sellers of Context Therapeutics shares for the quarter ending December 2025 were MPM BioImpact LLC (4.03Mn), Avidity Partners Management LP (3.48Mn), Nantahala Capital Management, LLC (1.62Mn), Clear Harbor Asset Management, LLC (92.8K), CITADEL ADVISORS LLC (68.98K).
• Per Business Quant, the top 10 investors in CNTX for the quarter ending December 2025 include Blue Owl Capital Holdings LP (14.87Mn), MPM BioImpact LLC (10.68Mn), Nextech Invest, Ltd. (7.42Mn), Deep Track Capital, LP (7.42Mn), Avidity Partners Management LP (5.5Mn), GREAT POINT PARTNERS LLC (4.68Mn), Franklin Resources Inc (4.0Mn), VANGUARD GROUP INC (3.79Mn), MILLENNIUM MANAGEMENT LLC (2.6Mn), MARSHALL WACE, LLP (2.59Mn).